MX2021007437A - Formas deuteradas y derivados de volinanserina. - Google Patents
Formas deuteradas y derivados de volinanserina.Info
- Publication number
- MX2021007437A MX2021007437A MX2021007437A MX2021007437A MX2021007437A MX 2021007437 A MX2021007437 A MX 2021007437A MX 2021007437 A MX2021007437 A MX 2021007437A MX 2021007437 A MX2021007437 A MX 2021007437A MX 2021007437 A MX2021007437 A MX 2021007437A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- compounds
- volinanserin
- deuterated forms
- disease
- Prior art date
Links
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical class COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000028017 Psychotic disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000022610 schizoaffective disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
- 229950002976 volinanserin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784056P | 2018-12-21 | 2018-12-21 | |
| PCT/US2019/067885 WO2020132461A1 (en) | 2018-12-21 | 2019-12-20 | Deuterated forms and derivatives of volinanserin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007437A true MX2021007437A (es) | 2021-09-08 |
Family
ID=71101633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007437A MX2021007437A (es) | 2018-12-21 | 2019-12-20 | Formas deuteradas y derivados de volinanserina. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220106272A1 (enExample) |
| EP (1) | EP3897507A4 (enExample) |
| JP (2) | JP7548906B2 (enExample) |
| KR (1) | KR20210124976A (enExample) |
| CN (1) | CN113747870B (enExample) |
| AU (1) | AU2019403391A1 (enExample) |
| BR (1) | BR112021012082A8 (enExample) |
| CA (1) | CA3124399A1 (enExample) |
| EA (1) | EA202191731A1 (enExample) |
| IL (1) | IL284201A (enExample) |
| MX (1) | MX2021007437A (enExample) |
| SG (1) | SG11202106692UA (enExample) |
| WO (1) | WO2020132461A1 (enExample) |
| ZA (1) | ZA202104656B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115057774A (zh) * | 2022-04-28 | 2022-09-16 | 北京绮一舟新材料技术有限公司 | 一种α-氘代羧酸衍生物类化合物及氘代药物的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2570961C (en) * | 2004-06-21 | 2015-09-01 | University Of Mississippi | Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities |
| US8198305B2 (en) * | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
| EP2185687A4 (en) * | 2007-08-06 | 2010-11-17 | Merck Sharp & Dohme | TREATMENT OF PSYCHOSES WITH A 5HT2A ANTAGONIST AND AN AGONIST OR AMPLIFIER OF A METABOTROPIC GLUTAMATE RECEPTOR |
| US8609673B2 (en) * | 2008-01-22 | 2013-12-17 | Concert Pharmaceuticals, Inc. | Vandetanib derivatives |
| WO2012039660A1 (en) * | 2010-09-20 | 2012-03-29 | A. Carlsson Research Ab | Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders |
| SG194625A1 (en) * | 2011-05-23 | 2013-12-30 | Sanofi Sa | Process for the preparation of deuterated compounds containing n-alkyl groups |
| LT3135656T (lt) * | 2011-06-20 | 2019-04-25 | H. Lundbeck A/S | Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui |
| WO2014145718A2 (en) * | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
| WO2018023009A1 (en) * | 2016-07-29 | 2018-02-01 | Concert Pharmaceuticals, Inc. | Deuterated lurasidone |
-
2019
- 2019-12-20 MX MX2021007437A patent/MX2021007437A/es unknown
- 2019-12-20 EP EP19900289.0A patent/EP3897507A4/en active Pending
- 2019-12-20 KR KR1020217022981A patent/KR20210124976A/ko not_active Ceased
- 2019-12-20 EA EA202191731A patent/EA202191731A1/ru unknown
- 2019-12-20 CN CN201980092743.7A patent/CN113747870B/zh active Active
- 2019-12-20 CA CA3124399A patent/CA3124399A1/en active Pending
- 2019-12-20 US US17/416,011 patent/US20220106272A1/en not_active Abandoned
- 2019-12-20 JP JP2021535751A patent/JP7548906B2/ja active Active
- 2019-12-20 SG SG11202106692UA patent/SG11202106692UA/en unknown
- 2019-12-20 WO PCT/US2019/067885 patent/WO2020132461A1/en not_active Ceased
- 2019-12-20 AU AU2019403391A patent/AU2019403391A1/en not_active Abandoned
- 2019-12-20 BR BR112021012082A patent/BR112021012082A8/pt not_active Application Discontinuation
-
2021
- 2021-06-20 IL IL284201A patent/IL284201A/en unknown
- 2021-07-05 ZA ZA2021/04656A patent/ZA202104656B/en unknown
-
2024
- 2024-08-29 JP JP2024147359A patent/JP2024163142A/ja active Pending
- 2024-11-08 US US18/941,426 patent/US20250066302A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202106692UA (en) | 2021-07-29 |
| IL284201A (en) | 2021-08-31 |
| JP2024163142A (ja) | 2024-11-21 |
| JP7548906B2 (ja) | 2024-09-10 |
| KR20210124976A (ko) | 2021-10-15 |
| AU2019403391A1 (en) | 2021-08-05 |
| US20250066302A1 (en) | 2025-02-27 |
| BR112021012082A8 (pt) | 2023-03-21 |
| US20220106272A1 (en) | 2022-04-07 |
| WO2020132461A1 (en) | 2020-06-25 |
| EP3897507A1 (en) | 2021-10-27 |
| CA3124399A1 (en) | 2020-06-25 |
| BR112021012082A2 (pt) | 2021-08-31 |
| CN113747870A (zh) | 2021-12-03 |
| CN113747870B (zh) | 2025-08-01 |
| EP3897507A4 (en) | 2022-09-14 |
| JP2022515156A (ja) | 2022-02-17 |
| ZA202104656B (en) | 2022-10-26 |
| EA202191731A1 (ru) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| MX2022016276A (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| MY195742A (en) | Isoindoline-1-One Derivatives as Cholinergic Muscarinic M1 Receptor Positive Alloesteric Modulator Activity for the Treatment of Alzheimers Disease | |
| MX386258B (es) | Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas | |
| TW201129562A (en) | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | |
| ZA202306172B (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| WO2021016112A3 (en) | Non-sedating dexmedetomidine treatment regimens | |
| TN2015000382A1 (en) | Perfluorinated cyclopropyl fused 1,3- oxazin -2- amine compounds as beta- secretase inhibitors and methods of use | |
| MX366855B (es) | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. | |
| TW200801029A (en) | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | |
| SG10201903579SA (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| JOP20220063A1 (ar) | مشتقات بيريدازين-3(2h)-أون ملتحمة بأزول | |
| TN2018000322A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| PH12018502457B1 (en) | Treatment for parkinson's disease | |
| MX2009009466A (es) | Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro. | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| JO3569B1 (ar) | مركبات بروبيل حلقي متحد مع ثيازين-2-أمين كمثبطات انزيم بيتا سكريتاز وطرق استخدامها | |
| MX394391B (es) | Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso. | |
| MX2024010655A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| TN2020000160A1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| TR201819805T4 (tr) | Flavaglin türevleri̇. | |
| FI3541784T3 (fi) | Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina | |
| EA202191731A1 (ru) | Дейтерированные формы и производные волинансерина | |
| MX2020009334A (es) | Compuestos para tratar la enfermedad de alzheimer. |